262 related articles for article (PubMed ID: 18986281)
1. Placebo-controlled trials of treatments for community-acquired pneumonia: review of the literature and discussion of feasibility and potential value.
Murphy TF
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S145-9. PubMed ID: 18986281
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
Echols RM; Tillotson GS; Song JX; Tosiello RL
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
[TBL] [Abstract][Full Text] [Related]
3. Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumonia.
Bradley JS; McCracken GH
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S241-8. PubMed ID: 18986297
[TBL] [Abstract][Full Text] [Related]
4. Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy.
Niven DJ; Laupland KB
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):69-81. PubMed ID: 19622058
[TBL] [Abstract][Full Text] [Related]
5. [Acute community-acquired pneumonia. A review of clinical trials].
Chidiac C
Med Mal Infect; 2006; 36(11-12):650-66. PubMed ID: 16876363
[TBL] [Abstract][Full Text] [Related]
6. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
Segreti J; House HR; Siegel RE
Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
[TBL] [Abstract][Full Text] [Related]
7. What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.
File TM; Schentag JJ
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S157-65. PubMed ID: 18986283
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
[TBL] [Abstract][Full Text] [Related]
9. Predictors of symptom resolution in patients with community-acquired pneumonia.
Marrie TJ; Lau CY; Wheeler SL; Wong CJ; Feagan BG
Clin Infect Dis; 2000 Dec; 31(6):1362-7. PubMed ID: 11096003
[TBL] [Abstract][Full Text] [Related]
10. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
Bartlett JG
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295
[TBL] [Abstract][Full Text] [Related]
11. Community-acquired pneumonia.
Carbonara S; Monno L; Longo B; Angarano G
Curr Opin Pulm Med; 2009 May; 15(3):261-73. PubMed ID: 19387263
[TBL] [Abstract][Full Text] [Related]
12. Overview of recent studies of community-acquired pneumonia.
Higgins K; Singer M; Valappil T; Nambiar S; Lin D; Cox E
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S150-6. PubMed ID: 18986282
[TBL] [Abstract][Full Text] [Related]
13. The role of new therapies for severe community-acquired pneumonia.
Restrepo MI; Anzueto A
Curr Opin Infect Dis; 2006 Dec; 19(6):557-64. PubMed ID: 17075331
[TBL] [Abstract][Full Text] [Related]
14. Clinical end points of therapy for patients with mild community-acquired pneumonia.
Gilbert DN
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S140-4. PubMed ID: 18986280
[TBL] [Abstract][Full Text] [Related]
15. Historical and regulatory perspectives on the treatment effect of antibacterial drugs for community-acquired pneumonia.
Singer M; Nambiar S; Valappil T; Higgins K; Gitterman S
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S216-24. PubMed ID: 18986293
[TBL] [Abstract][Full Text] [Related]
16. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents.
Roig J; Casal J; Gispert P; Gea E
Med Mal Infect; 2006; 36(11-12):680-9. PubMed ID: 17095177
[TBL] [Abstract][Full Text] [Related]
17. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
Pertel PE; Bernardo P; Fogarty C; Matthews P; Northland R; Benvenuto M; Thorne GM; Luperchio SA; Arbeit RD; Alder J
Clin Infect Dis; 2008 Apr; 46(8):1142-51. PubMed ID: 18444848
[TBL] [Abstract][Full Text] [Related]
18. Spectrum of microbial etiology of community-acquired pneumonia in hospitalized patients: implications for selection of the population for enrollment in clinical trials.
Mandell LA
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S189-92. PubMed ID: 18986288
[TBL] [Abstract][Full Text] [Related]
19. Is it possible to blind a trial for community-acquired pneumonia?
Boucher HW
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S210-5. PubMed ID: 18986292
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic treatment of community acquired pneumonia varies widely across Germany.
Kohlhammer Y; Raspe H; Marre R; Suttorp N; Welte T; Schäfer T;
J Infect; 2007 May; 54(5):446-53. PubMed ID: 17007933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
